Table 2 Baseline characteristics: comparison of COPD subjects within the tiotropium or long acting beta-agonists/inhaled corticosteroid groups
|  | TIO | ICS ± LABA | p-value |
|---|---|---|---|
Gender (female, %) | 46.9 | 48.6 | 0.7 |
Race (Non-Hispanic White, %) | 86.3 | 82.2 | 0.2 |
Oxygen Therapy (%) | 27.7 | 26.3 | 0.7 |
Chronic Bronchitis (%) | 25.4 | 29.6 | 0.2 |
Doctor's Diagnosis of Asthma (%) | 16.0 | 39.3 | <0.001 |
Frequent Cough Symptom (%) | 46.1 | 46.0 | 1.0 |
Frequent Phlegm Symptom (%) | 44.9 | 52.2 | 0.06 |
Hay Fever (%) | 30.9 | 37.4 | 0.2 |
GERD (%) | 33.2 | 35.0 | 0.7 |
Cardiovascular disease (%) | 24.6 | 20.5 | 0.2 |
Age (years) | 66.3 | 64.6 | 0.006 |
Current Smoking | 34.4 | 32.2 | 0.6 |
Pack-Years of Smoking | 53.5 | 52.8 | 0.7 |
6MWT distance (ft) | 1216 | 1206 | 0.7 |
FEV1 percent predicted | 54.4 | 53.1 | 0.3 |
FEV1/FVC | 0.49 | 0.50 | 0.5 |
MMRC Score | 2.0 | 2.3 | 0.006 |
SGRQ Total Score | 38.9 | 42.6 | 0.007 |
BODE score | 2.6 | 2.9 | 0.02 |
TLC by CT percent predicted | 101.9 | 104.3 | 0.04 |
SRWA-Pi10 | 3.70 | 3.73 | 0.003 |
Percent Emphysema | 12.7 | 12.7 | 1.0 |
Percent Gas Trapping | 39.0 | 39.3 | 0.8 |
BMI (kg/m^2) | 27.8 | 28.4 | 0.2 |
Exacerbations/Year in Follow-Up | 0.5 | 0.7 | 0.004 |